<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3801">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330381</url>
  </required_header>
  <id_info>
    <org_study_id>SPD555-303</org_study_id>
    <secondary_id>M0001-C303</secondary_id>
    <secondary_id>2010-022402-40</secondary_id>
    <nct_id>NCT01330381</nct_id>
  </id_info>
  <brief_title>Prucalopride in Pediatric Subjects With Functional Constipation</brief_title>
  <acronym>FC</acronym>
  <official_title>Trial Consisting of an 8-week Double-blind Placebo-controlled Part to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of Prucalopride in Paediatric Subjects With Functional Constipation, Aged ≥6 Months to &lt;18 Years, Followed by a 16-week Open-label Comparator (PEG) Controlled Part, to Document Safety and Tolerability up to 24 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Hungary:</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of prucalopride compared to placebo for the treatment of functional
      constipation in a paediatric population, aged ≥ 6 months to &lt; 18 years. A 16-week open-label
      comparator (PEG) controlled part will follow, to document safety and tolerability up to 24
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent of Responders in the Last Four Weeks of the Double-Blind Treatment Period</measure>
    <time_frame>Last 4 weeks of double-blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Responders are defined as subjects with an average spontaneous defecation frequency is ≥3 times per week AND the average number of fecal incontinence episodes per 2 weeks is ≤ 1 episode (only for subjects after acquisition of toileting skills).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Bowel Frequency of 3 or More Spontaneous Bowel Movements (SBM) Per Week in the Last Four Weeks of the Double-Blind Treatment Period</measure>
    <time_frame>Last 4 weeks of double-blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Fecal Incontinence Episodes of 1 or Less Per 2 Weeks in the Last Four Weeks of the Double-Blind Treatment Period</measure>
    <time_frame>Last 4 weeks of double-blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fecal incontinence is a lack of control over defecation, leading to involuntary loss of bowel contents (only for subjects after acquisition of toileting skills).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Retentive Posturing or Excessive Volitional Stool Retention in the Double-Blind Treatment Period</measure>
    <time_frame>Over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Purposefully avoiding defecation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Painful Bowel Movements Score in the Double-Blind Treatment Period</measure>
    <time_frame>Over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain was rated on a 6-point scale (0=no hurt, 1=hurts little bit, 2=hurts little more, 3=hurts even more, 4=hurts whole lot, 5=hurts worst) in subjects of 3 years and older. Lower scores represent less pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency Per SBM Score in Children Without Diapers in the Double-Blind Treatment Period</measure>
    <time_frame>Over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using the 7-point Bristol scale where 1-2 indicate constipation, 3-4 are ideal stools, and 5-7 tending toward diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency Per SBM Score in Children With Diapers in the Double-Blind Treatment Period</measure>
    <time_frame>Over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured on a 4-point scale where 1 is constipation, 2-3 is ideal, and 4 is diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Large Diameter Stools in the Double-Blind Treatment Period</measure>
    <time_frame>Over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Large diameter stools make defecation more difficult. Small diameter stools are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Pain Score in Double-Blind Treatment Period</measure>
    <time_frame>Over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain was rated on a 6-point scale (0=no hurt, 1=hurts little bit, 2=hurts little more, 3=hurts even more, 4=hurts whole lot, 5=hurts worst) in subjects of 3 years and older. Lower scores represent less pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Toilet Training in the Double-Blind Treatment Period</measure>
    <time_frame>Over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Only for subjects after acquisition of toileting skills.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Rescue Medications Taken in the Double-Blind Treatment Period</measure>
    <time_frame>Over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First SBM in the Double-Blind Treatment Period</measure>
    <time_frame>Day 1 onwards</time_frame>
    <safety_issue>No</safety_issue>
    <description>After intake of the trial medication on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of SBM Per Week in the Double-Blind Treatment Period</measure>
    <time_frame>Over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of SBM Per Week Over the 8 Week Double Blind Treatment Period</measure>
    <time_frame>Baseline and over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Constipation Over the Past 2 Weeks for the Final On Treatment Assessment in the Double-Blind Treatment Period</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Constipation Over the Past 2 Weeks for the Final On Treatment Assessment in the Open-Label Treatment Period</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Treatment for Final On Treatment Assessment in Double-Blind Treatment Period</measure>
    <time_frame>Over the 8 week double blind treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Treatment for Final On Treatment Assessment in Open-Label Treatment Period</measure>
    <time_frame>Over the 16 week open label treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Convenience of Treatment for Final On Treatment Assessment in Open-Label Treatment Period</measure>
    <time_frame>Over the 16 week open label treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Functional Constipation</condition>
  <arm_group>
    <arm_group_label>prucalopride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG 4000</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4-20g administered as an oral solution once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prucalopride</intervention_name>
    <description>prucalopride
subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml
subjects with weight &gt;50 kg: prucalopride 2 mg tablet once daily</description>
    <arm_group_label>prucalopride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching oral solution or oral tablets given once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG 4000</intervention_name>
    <arm_group_label>PEG 4000</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Boys and girls, aged ≥ 6 months and &lt; 18 years.

          2. Subjects with a confirmed diagnosis of functional constipation as defined by the Rome
             III criteria.

        Main Exclusion Criteria:

          1. Children with underlying GI abnormalities and causes for defecation disorders.

          2. Constipation is thought to be drug-induced.

          3. Subjects suffering from secondary causes of chronic constipation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Mugie SM, Korczowski B, Bodi P, Green A, Kerstens R, Ausma J, Ruth M, Levine A, Benninga MA. Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology. 2014 Dec;147(6):1285-95.e1. doi: 10.1053/j.gastro.2014.09.005. Epub 2014 Sep 16.</citation>
    <PMID>25239590</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 13, 2015</lastchanged_date>
  <firstreceived_date>April 4, 2011</firstreceived_date>
  <firstreceived_results_date>January 7, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects who completed the 8 week double blind treatment period and wished to continue were re-randomized after the double-blind treatment period to the 16 week open-label treatment period. Out of 215 subjects randomized in the study, 213 subjects received treatment and 2 subjects withdrew consent before treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prucalopride</title>
          <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution.
Subjects with weight &gt;50 kg received placebo matching prucalopride oral tablet.</description>
        </group>
        <group group_id="P3">
          <title>PEG 4000 (Polyethylene Glycol)</title>
          <description>Subjects received PEG 4000 oral solution at a dose of 4 gram to 20 gram once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Treatment Period (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not fulfill inclusion/exclusion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Treatment Period (16 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set was used for baseline characteristics. The Safety Set includes all subjects who were randomized and received at least 1 dose of investigational product. One randomized subject in each group did not receive investigational product and therefore were not included in the Safety Set.</population>
      <group_list>
        <group group_id="B1">
          <title>Prucalopride</title>
          <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="106"/>
                <measurement group_id="B2" value="107"/>
                <measurement group_id="B3" value="213"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="106"/>
                <measurement group_id="B2" value="107"/>
                <measurement group_id="B3" value="213"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8.3" spread="4.54"/>
                <measurement group_id="B2" value="8.2" spread="4.69"/>
                <measurement group_id="B3" value="8.3" spread="4.61"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="58"/>
                <measurement group_id="B3" value="118"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="49"/>
                <measurement group_id="B3" value="95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hungary</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="74"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Netherlands</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Poland</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="46"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Belgium</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Italy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Responders in the Last Four Weeks of the Double-Blind Treatment Period</title>
        <description>Responders are defined as subjects with an average spontaneous defecation frequency is ≥3 times per week AND the average number of fecal incontinence episodes per 2 weeks is ≤ 1 episode (only for subjects after acquisition of toileting skills).</description>
        <time_frame>Last 4 weeks of double-blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Responders in the Last Four Weeks of the Double-Blind Treatment Period</title>
            <description>Responders are defined as subjects with an average spontaneous defecation frequency is ≥3 times per week AND the average number of fecal incontinence episodes per 2 weeks is ≤ 1 episode (only for subjects after acquisition of toileting skills).</description>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17.0"/>
                  <measurement group_id="O2" value="17.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.9002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Bowel Frequency of 3 or More Spontaneous Bowel Movements (SBM) Per Week in the Last Four Weeks of the Double-Blind Treatment Period</title>
        <description>Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.</description>
        <time_frame>Last 4 weeks of double-blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Subjects With Bowel Frequency of 3 or More Spontaneous Bowel Movements (SBM) Per Week in the Last Four Weeks of the Double-Blind Treatment Period</title>
            <description>Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.</description>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29.2"/>
                  <measurement group_id="O2" value="35.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.3520</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Fecal Incontinence Episodes of 1 or Less Per 2 Weeks in the Last Four Weeks of the Double-Blind Treatment Period</title>
        <description>Fecal incontinence is a lack of control over defecation, leading to involuntary loss of bowel contents (only for subjects after acquisition of toileting skills).</description>
        <time_frame>Last 4 weeks of double-blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Subjects With Fecal Incontinence Episodes of 1 or Less Per 2 Weeks in the Last Four Weeks of the Double-Blind Treatment Period</title>
            <description>Fecal incontinence is a lack of control over defecation, leading to involuntary loss of bowel contents (only for subjects after acquisition of toileting skills).</description>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43.0"/>
                  <measurement group_id="O2" value="43.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5228</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Retentive Posturing or Excessive Volitional Stool Retention in the Double-Blind Treatment Period</title>
        <description>Purposefully avoiding defecation.</description>
        <time_frame>Over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Retentive Posturing or Excessive Volitional Stool Retention in the Double-Blind Treatment Period</title>
            <description>Purposefully avoiding defecation.</description>
            <units>retentions/week</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" spread="1.82"/>
                  <measurement group_id="O2" value="1.2" spread="1.71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Painful Bowel Movements Score in the Double-Blind Treatment Period</title>
        <description>Pain was rated on a 6-point scale (0=no hurt, 1=hurts little bit, 2=hurts little more, 3=hurts even more, 4=hurts whole lot, 5=hurts worst) in subjects of 3 years and older. Lower scores represent less pain.</description>
        <time_frame>Over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Painful Bowel Movements Score in the Double-Blind Treatment Period</title>
            <description>Pain was rated on a 6-point scale (0=no hurt, 1=hurts little bit, 2=hurts little more, 3=hurts even more, 4=hurts whole lot, 5=hurts worst) in subjects of 3 years and older. Lower scores represent less pain.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.3" spread="1.25"/>
                  <measurement group_id="O2" value="1.7" spread="1.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Consistency Per SBM Score in Children Without Diapers in the Double-Blind Treatment Period</title>
        <description>Measured using the 7-point Bristol scale where 1-2 indicate constipation, 3-4 are ideal stools, and 5-7 tending toward diarrhea.</description>
        <time_frame>Over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Stool Consistency Per SBM Score in Children Without Diapers in the Double-Blind Treatment Period</title>
            <description>Measured using the 7-point Bristol scale where 1-2 indicate constipation, 3-4 are ideal stools, and 5-7 tending toward diarrhea.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.8" spread="0.96"/>
                  <measurement group_id="O2" value="3.6" spread="1.17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Consistency Per SBM Score in Children With Diapers in the Double-Blind Treatment Period</title>
        <description>Measured on a 4-point scale where 1 is constipation, 2-3 is ideal, and 4 is diarrhea.</description>
        <time_frame>Over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Stool Consistency Per SBM Score in Children With Diapers in the Double-Blind Treatment Period</title>
            <description>Measured on a 4-point scale where 1 is constipation, 2-3 is ideal, and 4 is diarrhea.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" spread="0.47"/>
                  <measurement group_id="O2" value="2.0" spread="0.59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Large Diameter Stools in the Double-Blind Treatment Period</title>
        <description>Large diameter stools make defecation more difficult. Small diameter stools are better.</description>
        <time_frame>Over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Large Diameter Stools in the Double-Blind Treatment Period</title>
            <description>Large diameter stools make defecation more difficult. Small diameter stools are better.</description>
            <units>large diameter stools/week</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.7" spread="1.67"/>
                  <measurement group_id="O2" value="1.7" spread="1.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abdominal Pain Score in Double-Blind Treatment Period</title>
        <description>Pain was rated on a 6-point scale (0=no hurt, 1=hurts little bit, 2=hurts little more, 3=hurts even more, 4=hurts whole lot, 5=hurts worst) in subjects of 3 years and older. Lower scores represent less pain.</description>
        <time_frame>Over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="95"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Abdominal Pain Score in Double-Blind Treatment Period</title>
            <description>Pain was rated on a 6-point scale (0=no hurt, 1=hurts little bit, 2=hurts little more, 3=hurts even more, 4=hurts whole lot, 5=hurts worst) in subjects of 3 years and older. Lower scores represent less pain.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" spread="1.18"/>
                  <measurement group_id="O2" value="1.1" spread="1.15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Toilet Training in the Double-Blind Treatment Period</title>
        <description>Only for subjects after acquisition of toileting skills.</description>
        <time_frame>Over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                  <measurement group_id="O2" value="75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Frequency of Toilet Training in the Double-Blind Treatment Period</title>
            <description>Only for subjects after acquisition of toileting skills.</description>
            <units>toilet trainings/week</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.9" spread="2.47"/>
                  <measurement group_id="O2" value="5.1" spread="2.47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Rescue Medications Taken in the Double-Blind Treatment Period</title>
        <time_frame>Over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Rescue Medications Taken in the Double-Blind Treatment Period</title>
            <units>rescue medications/week</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="1.25"/>
                  <measurement group_id="O2" value="1.3" spread="1.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First SBM in the Double-Blind Treatment Period</title>
        <description>After intake of the trial medication on Day 1.</description>
        <time_frame>Day 1 onwards</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to First SBM in the Double-Blind Treatment Period</title>
            <description>After intake of the trial medication on Day 1.</description>
            <units>hours</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="67.00" lower_limit="49.42" upper_limit="101.17"/>
                  <measurement group_id="O2" value="99.75" lower_limit="73.75" upper_limit="204.00"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.377</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of SBM Per Week in the Double-Blind Treatment Period</title>
        <time_frame>Over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of SBM Per Week in the Double-Blind Treatment Period</title>
            <units>SBM/week</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" spread="2.35"/>
                  <measurement group_id="O2" value="2.1" spread="1.74"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of SBM Per Week Over the 8 Week Double Blind Treatment Period</title>
        <time_frame>Baseline and over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the Number of SBM Per Week Over the 8 Week Double Blind Treatment Period</title>
            <units>SBM/week</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" spread="2.35"/>
                  <measurement group_id="O2" value="1.0" spread="1.78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Constipation Over the Past 2 Weeks for the Final On Treatment Assessment in the Double-Blind Treatment Period</title>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Severity of Constipation Over the Past 2 Weeks for the Final On Treatment Assessment in the Double-Blind Treatment Period</title>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Absent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.5"/>
                  <measurement group_id="O2" value="5.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.4"/>
                  <measurement group_id="O2" value="18.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.4"/>
                  <measurement group_id="O2" value="27.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.2"/>
                  <measurement group_id="O2" value="24.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Very severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.5"/>
                  <measurement group_id="O2" value="24.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1599</p_value>
            <method>Van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Constipation Over the Past 2 Weeks for the Final On Treatment Assessment in the Open-Label Treatment Period</title>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>PEG 4000</title>
            <description>Subjects received PEG 4000 oral solution at a dose of 4 gram to 20 gram once daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="97"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Severity of Constipation Over the Past 2 Weeks for the Final On Treatment Assessment in the Open-Label Treatment Period</title>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Absent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24.7"/>
                  <measurement group_id="O2" value="46.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.5"/>
                  <measurement group_id="O2" value="16.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.5"/>
                  <measurement group_id="O2" value="9.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.5"/>
                  <measurement group_id="O2" value="15.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Very severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24.7"/>
                  <measurement group_id="O2" value="12.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0003</p_value>
            <method>Van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Treatment for Final On Treatment Assessment in Double-Blind Treatment Period</title>
        <time_frame>Over the 8 week double blind treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Efficacy of Treatment for Final On Treatment Assessment in Double-Blind Treatment Period</title>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Not at all effective</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.0"/>
                  <measurement group_id="O2" value="32.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Little bit effective</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.6"/>
                  <measurement group_id="O2" value="18.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderately effective</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.5"/>
                  <measurement group_id="O2" value="25.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Quite a bit effective</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.3"/>
                  <measurement group_id="O2" value="14.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Extremely effective</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.6"/>
                  <measurement group_id="O2" value="9.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4647</p_value>
            <method>Van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Treatment for Final On Treatment Assessment in Open-Label Treatment Period</title>
        <time_frame>Over the 16 week open label treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>PEG 4000</title>
            <description>Subjects received PEG 4000 oral solution at a dose of 4 gram to 20 gram once daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="97"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Efficacy of Treatment for Final On Treatment Assessment in Open-Label Treatment Period</title>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Not at all effective</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.9"/>
                  <measurement group_id="O2" value="15.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Little bit effective</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.3"/>
                  <measurement group_id="O2" value="5.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderately effective</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.6"/>
                  <measurement group_id="O2" value="11.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Quite a bit effective</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.6"/>
                  <measurement group_id="O2" value="21.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Extremely effective</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.6"/>
                  <measurement group_id="O2" value="46.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>Van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Convenience of Treatment for Final On Treatment Assessment in Open-Label Treatment Period</title>
        <time_frame>Over the 16 week open label treatment period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects who were randomized and received at least 1 dose of investigational product. Not all subjects in the Full Analysis Set had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Prucalopride</title>
            <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
          </group>
          <group group_id="O2">
            <title>PEG 4000</title>
            <description>Subjects received PEG 4000 oral solution at a dose of 4 gram to 20 gram once daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="97"/>
                  <measurement group_id="O2" value="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Convenience of Treatment for Final On Treatment Assessment in Open-Label Treatment Period</title>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.5"/>
                  <measurement group_id="O2" value="15.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Very difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0"/>
                  <measurement group_id="O2" value="2.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Quite difficult</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="5.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Quite easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.8"/>
                  <measurement group_id="O2" value="28.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Very easy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54.6"/>
                  <measurement group_id="O2" value="47.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.3044</p_value>
            <method>Van Elteren test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 24</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prucalopride (Double-blind Period)</title>
          <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Double-blind Period)</title>
          <description>Subjects with weight ≤50 kg received placebo matching to prucalopride oral solution. Subjects with weight &gt;50 kg received placebo matching to prucalopride oral tablet.</description>
        </group>
        <group group_id="E3">
          <title>Prucalopride (Open-label Period)</title>
          <description>Subjects with weight ≤50 kg received 0.04 mg/kg prucalopride once daily as oral solution of 0.4 mg/mL. Subjects with weight &gt;50 kg received prucalopride 2 mg oral tablet once daily.</description>
        </group>
        <group group_id="E4">
          <title>PEG 4000 (Open-label Period)</title>
          <description>Subjects received PEG 4000 oral solution at a dose of 4 gram to 20 gram once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E2" events="21" subjects_affected="12" subjects_at_risk="107"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="106"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire Development LLC</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
